title: Ranibizumab in South Korean and Taiwanese patients with age-related macular degeneration: primary outcome of the EXTEND III study.
authors.forename: Fenq-Lih
authors.initials: FL
authors.lastname: Lee
authors.forename: Oh-Woong
authors.initials: OW
authors.lastname: Kwon
authors.forename: Hum
authors.initials: H
authors.lastname: Chung
authors.forename: Chi-Chun
authors.initials: CC
authors.lastname: Lai
authors.forename: Shwu-Jiuan
authors.initials: SJ
authors.lastname: Sheu
authors.forename: Young-Hee
authors.initials: YH
authors.lastname: Yoon
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D044466:Asian People / Q000208:ethnology; D006801:Humans; D058449:Intravitreal Injections; D000069579:Ranibizumab; D056910:Republic of Korea / Q000453:epidemiology; D016037:Single-Blind Method; D013624:Taiwan / Q000453:epidemiology; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology; D057135:Wet Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy* / Q000208:ethnology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab